Literature DB >> 1266564

Interferon in the serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders.

M Degré, H Dahl, B Vandvik.   

Abstract

The presence of interferon (IF) was investigated in serum and cerebrospinal fluid (CSF) from neurological patients. Significant titres of IF were found both in the serum and in the CSF in about half of the patients suffering from acute encephalitis and from multiple sclerosis (MS), but not in patients suffering from various non-inflammatory disorders in the central nervous system (CNS) or in the peripheral nervous system (PNS), and not in the serum of healthy blood donors. Significant IF titres in the CSF were regularly associated with significant titres in the serum, but the converse was not true. Interferon levels were not correlated to cell counts in the CSF; nor to concentration of IgG and albumin in serum and CSF; nor to presence of electrophoretically oligoclonal IgG patterns; nor to hemagglutinating and gel-precipitation antibodies against measles. IF levels were lower in the serum of patients having reduced serum/CSF ratios for measles antibody than those with normal ratios. The data may indicate that MS is linked to factors which induce IF production in the CNS.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1266564     DOI: 10.1111/j.1600-0404.1976.tb04333.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  14 in total

1.  CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.

Authors:  P Nair; R Melarkode; D Rajkumar; E Montero
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

Review 2.  Clinical pharmacokinetics of interferons.

Authors:  R J Wills
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  Absence of immunoreactive interferon-alpha in CSF from patients with multiple sclerosis.

Authors:  R J Abbott; P D Giles; I Bolderson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-01       Impact factor: 10.154

4.  Immunoreactive IFN-gamma in CSF in neurological disorders.

Authors:  R J Abbott; I Bolderson; P J Gruer; R C Peatfield
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-07       Impact factor: 10.154

5.  Acyclovir monotherapy versus acyclovir plus beta-interferon in focal viral encephalitis in children.

Authors:  U Wintergerst; B H Belohradsky
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

6.  Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Ingo Kleiter; Jian Song; Dominika Lukas; Maruf Hasan; Bernhard Neumann; Andrew L Croxford; Xiomara Pedré; Nadine Hövelmeyer; Nir Yogev; Alexander Mildner; Marco Prinz; Elena Wiese; Kurt Reifenberg; Stefan Bittner; Heinz Wiendl; Lawrence Steinman; Christoph Becker; Ulrich Bogdahn; Markus F Neurath; Andreas Steinbrecher; Ari Waisman
Journal:  Brain       Date:  2010-03-30       Impact factor: 13.501

7.  Immune interferon in serum and synovial fluid in rheumatoid arthritis and related disorders.

Authors:  M DeGré; O J Mellbye; O Clarke-Jenssen
Journal:  Ann Rheum Dis       Date:  1983-12       Impact factor: 19.103

8.  Lack of correlation between impaired interferon production and natural killer activity of lymphocytes in multiple sclerosis.

Authors:  I Stöger; M Tálas; M Benczúr; E Gyódi; G G Petrányi; G Pálffy; B Kotsy
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

9.  Human fibroblast interferon in tears of patients with picornavirus epidemic conjunctivitis.

Authors:  M P Langford; M Yin-Murphy; Y M Ho; J C Barber; S Baron; G J Stanton
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

10.  Cerebrospinal fluid interleukin 1 like activity during chronic relapsing experimental allergic encephalomyelitis.

Authors:  J A Symons; R V Bundick; A J Suckling; M G Rumsby
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.